Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.
breast cancer
metastasis
nuclear medicine
theranostics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Mar 2020
29 Mar 2020
Historique:
received:
21
02
2020
revised:
03
03
2020
accepted:
05
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
3
4
2020
Statut:
epublish
Résumé
Breast cancer is the most common malignancy in women throughout the world. Metastatic dissemination to vital organs is the leading cause of breast cancer-related deaths. The treatment of metastases is mainly based on the primary tumor characteristics. However, breast cancer metastases exhibit high heterogeneity leading to different prognosis and therapeutic responses. Getting access to phenotype of metastases would allow better management of patients. The advent of theranostics in nuclear medicine has opened new opportunities for the diagnosis and treatment of cancer patients. The aim of this review is to provide an overview of current knowledge and future directions in nuclear medicine for therapeutic management of metastatic breast cancer patients.
Identifiants
pubmed: 32235331
pii: cancers12040821
doi: 10.3390/cancers12040821
pmc: PMC7226533
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Breast Cancer Res Treat. 2012 Feb;131(3):801-8
pubmed: 21455667
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
Int J Cancer. 2011 Nov 15;129(10):2522-6
pubmed: 21207426
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Cancer. 2006 Aug 15;107(4):696-704
pubmed: 16826579
Nat Rev Cancer. 2007 Nov;7(11):834-46
pubmed: 17957189
J Nucl Med. 2016 Oct;57(10):1523-1528
pubmed: 27151988
Lancet Oncol. 2005 Jul;6(7):520-8
pubmed: 15992701
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
Onco Targets Ther. 2017 Oct 03;10:4821-4828
pubmed: 29042793
Oncotarget. 2015 Dec 8;6(39):42081-90
pubmed: 26536664
J Nucl Med. 2017 Feb;58(2):293-299
pubmed: 27609789
J Clin Oncol. 2012 Jul 20;30(21):2601-8
pubmed: 22711854
Drug Des Devel Ther. 2015 Sep 11;9:5215-23
pubmed: 26392755
Tumour Biol. 2017 Jun;39(6):1010428317705519
pubmed: 28618966
Int J Cancer. 2008 Mar 1;122(5):999-1004
pubmed: 17973263
N Engl J Med. 2000 Feb 24;342(8):525-33
pubmed: 10684910
J Nucl Med. 2013 May;54(5):776-84
pubmed: 23487015
Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68
pubmed: 28613198
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Am J Surg. 1978 Sep;136(3):337-8
pubmed: 707701
Cancer. 1983 Aug 1;52(3):479-85
pubmed: 6861087
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
APMIS. 2008 Jul-Aug;116(7-8):754-70
pubmed: 18834417
Cell Signal. 2011 Dec;23(12):1952-60
pubmed: 21777670
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
EJNMMI Res. 2018 Sep 6;8(1):90
pubmed: 30191351
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815
pubmed: 28522448
Clin Cancer Res. 2002 Apr;8(4):1139-46
pubmed: 11948125
Oncologist. 2008 Aug;13(8):838-44
pubmed: 18650259
Cancer Res. 2008 May 1;68(9):3108-14
pubmed: 18451135
Int J Mol Sci. 2016 Jan 14;17(1):
pubmed: 26784176
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
FASEB J. 2011 Jul;25(7):2433-46
pubmed: 21478264
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Lancet. 2002 Aug 31;360(9334):683-9
pubmed: 12241875
Theranostics. 2014 Apr 25;4(7):708-20
pubmed: 24883121
J Nucl Med. 2013 Nov;54(11):1869-75
pubmed: 24029656
J Immunol Res. 2015;2015:268172
pubmed: 25883990
Cancer Cell. 2008 Jan;13(1):58-68
pubmed: 18167340
Mol Cell. 2015 Nov 19;60(4):537-46
pubmed: 26590713
Breast Cancer (Auckl). 2015 Sep 01;9(Suppl 1):23-34
pubmed: 26380552
Cancer Lett. 2010 Aug 28;294(2):139-46
pubmed: 20363069
J Clin Invest. 2010 Jun;120(6):2030-9
pubmed: 20501944
Theranostics. 2018 Jun 7;8(13):3559-3570
pubmed: 30026866
Int J Cancer. 2019 Jan 15;144(2):263-272
pubmed: 30368776
Med Sci (Paris). 2012 Dec;28(12):1116-9
pubmed: 23290413
Ann Oncol. 2012 Sep;23 Suppl 10:x349-53
pubmed: 22987990
Ann Oncol. 2008 Dec;19(12):2012-9
pubmed: 18641006
DNA Repair (Amst). 2012 Jan 2;11(1):12-21
pubmed: 22112864
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Clin Transl Oncol. 2015 Dec;17(12):946-55
pubmed: 26683474
Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):94-101
pubmed: 27069769
Front Oncol. 2013 Aug 19;3:215
pubmed: 23967404
Mol Oncol. 2016 Oct 7;11(1):62-78
pubmed: 28017284
Br J Cancer. 2015 May 12;112(10):1617-25
pubmed: 25880006
Oncol Res Treat. 2014;37(11):622-6
pubmed: 25427579
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
Oncologist. 2008;13 Suppl 3:21-6
pubmed: 18458121
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
Bioorg Med Chem. 2014 Mar 1;22(5):1700-7
pubmed: 24503274
Crit Rev Oncol Hematol. 2018 Mar;123:7-20
pubmed: 29482781
Dalton Trans. 2015 Mar 21;44(11):4819-44
pubmed: 25406520
Mini Rev Med Chem. 2016;16(14):1134-66
pubmed: 26996617
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
J Nucl Med. 1991 Aug;32(8):1526-31
pubmed: 1869973
J Nucl Med. 2016 Sep;57(9):1334-8
pubmed: 27056618
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Lancet Oncol. 2019 Apr;20(4):546-555
pubmed: 30846327
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42
pubmed: 12808139
Cancer Manag Res. 2019 May 10;11:4371-4390
pubmed: 31191001
Pathol Res Pract. 2013 Dec;209(12):797-802
pubmed: 24183366
Cancer Res. 2014 Jun 1;74(11):2907-12
pubmed: 24824231
Breast Cancer Res. 2016 Jan 19;18(1):8
pubmed: 26781299
J Nucl Med. 2018 Jul;59(7):1056-1062
pubmed: 29572256
Cancer. 1977 May;39(5):2194-200
pubmed: 870169
Ann Biol Clin (Paris). 2016 Dec 1;74(6):653-660
pubmed: 27848916
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
Breast. 2012 Jun;21(3):284-8
pubmed: 22212746
Curr Radiopharm. 2016;9(3):244-257
pubmed: 27774910
Int J Clin Exp Pathol. 2015 Jan 01;8(1):914-21
pubmed: 25755795
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
J Cancer Res Clin Oncol. 2013 Sep;139(9):1569-77
pubmed: 23892409
J Surg Sci. 2013 Dec;1(1):3-7
pubmed: 24818173
Mol Imaging. 2019 Jan-Dec;18:1536012118823473
pubmed: 30799684
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Nucl Med. 2009 Jun;50(6):974-81
pubmed: 19443585
J Clin Oncol. 2001 Jun 1;19(11):2797-803
pubmed: 11387350
Int J Nanomedicine. 2016 Dec 19;12:53-60
pubmed: 28053523
J Nucl Med. 2017 Sep;58(9):1401-1407
pubmed: 28280221
J Surg Oncol. 2017 Dec;116(8):1021-1028
pubmed: 28767137
J Natl Cancer Inst. 2010 Apr 7;102(7):456-63
pubmed: 20220104
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712
pubmed: 31776632
Nat Rev Cancer. 2008 May;8(5):329-40
pubmed: 18404148
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165